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ABSTRACT
The current COVID-19 or Sars-CoV-2 pandemic increased awareness of hyposmia or anosmia, as this can be an accompanying symp-
tom. In mild cases, anosmia without rhinorrhea can be the only presenting symptom of this infection. Timely identification can lead 
to early detection of otherwise asymptomatic carriers. History taking and essential clinical assessment with appropriate protective 
measures can be performed in patients in whom COVID-19 is suspected. Patients with anosmia without nasal obstruction should be 
considered COVID-19 suspect and this should initiate testing or self-isolation. As for treatment of hyposmia or anosmia, the authors 
do not advise treatment with systemic corticosteroids in patients with COVID-19. Based on expert opinion, nasal corticosteroids can 
be considered, with a preference for spray formulation. Patients who were already using topical or inhalation corticosteroids for proven 
pre-existing disease (such as asthma and/or allergy) should be advised to continue their maintenance therapy. ENT (Ear Nose Throat) 
focus on hyposmia and anosmia should be continued, to gain additional knowledge of the disease mechanisms of COVID-19 and im-
prove follow-up, not only on the pneumological aspects but also to evaluate the impact on quality of life of potentially long-term side 
effects caused by anosmia.
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Introduction on olfactory (dys)function
Olfactory function is part of the chemosensory system and im-
portant for digestive behavior as it helps to detect and enjoy 
food. In addition, it is of importance for social communication 
and the detection of environmental hazards (1). Processing 
of olfactory information includes smell receptor stimulation 
in the olfactory mucosa, adequate neural transmission by the 
olfactory nerves and processing by the olfactory bulb, parts of 
the limbic system and the neocortex (2).
Olfactory disorders such as anosmia and hyposmia are es-
timated to affect 3–20% of the population (1). Apart from 
aging, three major causative disorders have been identified. 
Typically, in tertial referral centers these causes include na-
sal and paranasal sinus disease (21%), infections of the up-
per respiratory tract (19%), and head trauma (14%). In 22% 
of patients no identifiable cause is found (3, 4). Other po-
tential causes include neurodegenerative diseases, structur-
al brain disease, toxic chemical exposure, metabolic diseases 
and side effects of medication or drugs (2, 5). Improvement 
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in olfactory function is inversely correlated with the severity 
and duration of loss of smell, age, smoking, and male sex; up to 
one-half of patients with olfactory dysfunction improves over 
time, although for post-traumatic loss improvement is noted 
only around 10-20% (5). As for (post-)infectious olfactory dis-
orders, the pathophysiology remains poorly delineated, but is 
thought to involve either damage to the olfactory neuroepi-
thelium (peripheral) or central olfactory processing pathways 
and can persist in 6-13% of cases (6-11). It was demonstrated 
that 80% of the patients with post-viral olfactory loss report-
ed subjective recovery after one year, but only 32% reported 
normosmia; the more favorable prognosis was associated with 
longer follow-up duration and female gender (12). The varying 
rates and degree of post-infectious olfactory dysfunction can 
be explained by the differences in affecting the central olfac-
tory pathways (2, 6).
Depending on the specific cause, standard treatment of ol-
factory disorders in the course of chronic rhinosinusitis usu-
ally includes intranasal corticosteroid and oral corticosteroid 
treatment. The routine work-up of patients with taste or smell 
disorders includes a thorough structured history, ENT exam-
ination as well as neurologic examination (focusing on crani-
al nerves I, VII, IX, and X) and additional assessment including 
computed tomography (CT) and/or brain magnetic resonance 
imaging (MRI) (5, 13). A well-specified history is also import-
ant to distinguish between smell and taste disorders, as com-
plaints of taste loss usually reflect loss of smell function (14). 
Numerous techniques are available in the clinic for the inves-
tigation of chemosensory function and psychophysical testing 
using orthonasal and retronasal stimulation routes helps to 
distinguish anosmic from hyposmic patients (15). These psy-
chophysical tests are needed to objectively verify the patient’s 
complaints which can often be misleading (16, 17). Olfactory 
training appears to be a promising therapy for patients with 
post-viral olfactory loss to partly regain their sense of smell 
(18).
COVID-19 and olfactory dysfunction
Currently, the World Health Organization (WHO) has an-
nounced a pandemic infection with a previously unknown 
species of coronavirus, called COVID-19 or SARS-CoV-2. This 
infection is transmitted mainly through droplets and aerosols, 
and, causes mild symptoms in the majority of cases. The most 
common symptoms are fever, dry cough, fatigue, anorex-
ia and myalgia; less common symptoms include headache, 
sore throat, rhinorrhea, and gastrointestinal symptoms (e.g., 
nausea and diarrhea) (19). Life-threatening complications of 
COVID-19 are acute respiratory distress syndrome (ARDS), ar-
rythmia, myocardial injury and shock (20).
Recent studies report anosmia and dysgeusia as two of the 
first symptoms of COVID-19 (21, 22). Dysgeusia could be the 
result of an altered perception of taste caused by the loss of 
sense of smell, and it might actually point towards a confusion 
of taste and retronasal olfactory function, i.e. flavor (23, 24). 
Olfactory dysfunction has been reported as the only symptom 
in patients with very mild disease. The COVID-19 pandemic 
has thus led to increased awareness of hyposmia and anosmia, 
as reports from epicenters show that smell and taste disorders 
can be first signs of this infection (25-27). There is anecdot-
al information about the prevalence, onset, and evolution of 
anosmia, hyposmia and dysgeusia in COVID-19 patients. The 
first data on anosmia in patients are published by clinicians in 
the field and spread by special reports of medical associations 
(21, 28).
In a survey of 59 COVID-19 patients by Giacomelli et al. (29), 
twenty patients (33.9%) reported at least one taste or olfac-
tory disorder(s) and eleven participants (18.6%) reported both. 
These authors state that olfactory dysfunction is frequently 
related to COVID-19 infection and may precede the onset of 
the disease. The authors refer to the underlying mechanisms 
as described in mouse models by Netland et al. (30), that 
demonstrate that SARS-CoV enters the brain primarily via 
the olfactory bulb, and infection results in rapid, transneuro-
nal spread to connected areas of the brain. Brann et al. (31) 
reported that ACE-2 receptor, the main host cell receptor of 
2019-nCoV playing a crucial role in the entry of virus into the 
cell to cause the final infection, is expressed on the mucosa of 
oral cavity and highly enriched in epithelial cells of the tongue. 
Particularly at the level of the olfactory epithelium, ACE-2 and 
TMPRSS2 genes are expressed by olfactory sustentacular cells 
and olfactory stem cells.
Eliezer et al. (32) reported a case where the main symptom 
expressed by the patient infected by SARS-CoV-2 was the 
sudden and complete loss of the olfactory function without 
nasal obstruction. They report that cases of sudden and com-
plete olfactory function loss without nasal obstruction in a 
patient with other symptoms, such as cough or fever, should 
alert the clinician to suspect SARS-CoV-2 infection. Vaira 
et al. (21) report olfactory dysfunction based on history and 
physical examination in 19.4% out of 320 patients. Kaye et 
al. reported the initial findings of the anosmia reporting tool 
on COVID-19 cases for clinicians worldwide (23). Out of 237 
entries they noted anosmia prior to COVID-19 diagnosis in 
73% while anosmia was the initial symptom in 26.6% of the 
patients. A recent European multicenter study by Lechien et 
al. (33) investigated self-reported olfactory dysfunction in 417 
mild to moderate COVID-19 cases. Olfactory dysfunction was 
reported in 85.6% of cases and this occurred in 11.8% before 
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Main Points:
• Patients with anosmia without nasal obstruction should be 
considered COVID-19 suspect and this should initiate test-
ing or self-isolation.
• Based on currently available literature, the authors do not ad-
vise treatment with systemic corticosteroids.
• Although there is no evidence-based indication for intranasal 
corticosteroid, based on expert opinion, the use of intrana-
sal corticosteroids can be considered, with a preference for 
spray formulation.
• Patients who were already using topical or inhalation corti-
costeroids for proven pre-existing disease (such as asthma 
and/or allergy) should be advised to continue their mainte-
nance therapy.
• Follow-up of olfactory function is indicated and olfactory 
training can be started in cases where olfactory dysfunction 
persists.
the presence of other symptoms. Out of the 18.2% of patients 
without nasal obstruction or rhinorrhea, 79.7% were hyposmic 
or anosmic.
However, a study from China reported that the ratio of pa-
tients complaining of loss of smell and loss of taste was only 
5.1% and 5.6% respectively (34). Yan et al. (35) included a 
total of 1480 patients with influenza-like symptoms that 
underwent COVID-19 testing. Smell and taste loss were re-
ported in 68% and 71% of COVID-19 positive subjects, re-
spectively, compared to 16% and 17% of COVID-19 nega-
tive patients (p<0.001). Klopfenstein et al. (36) analysed 114 
confirmed COVID-19 patients and the results demonstrated 
anosmia to be present in 47%, associated with dysgeusia in 
85%, of cases. Anosmia was never the first or second symp-
tom to develop, but it was the third symptom in 38% of cas-
es. Anosmia developed 4.4 days after infection onset. The 
first study using smell quantitative assessment (University of 
Pennsylvania Smell Identification Test / UPSIT) demonstrat-
ed that 98% of COVID-19 patients (n=60) exhibited at least 
some smell dysfunction. Thirty-five of the 60 patients (58%) 
were either anosmic (25%) or severely hyposmic (33%) (37). 
The varying rates might be explained by differences in clini-
cal work-up, specific regional patient characteristics or viral 
strains.
In the current issue of B-ENT (March 2020), the group of Ca-
pelli et al. (38) describes a statistically significant increase in 
the incidence of hyposmia in the Lombardy city of Codogno, 
in the epicenter of the COVID-19 outbreak in Italy, in the pe-
riod between February 21 and March 15, 2020 compared to 
the incidence of the same symptom in other periods. This and 
other research will lead to further investigations to determine 
whether or not hyposmia can be part of the case definition of 
COVID-19 and what the outcome is after long-term follow-up.
As for the treatment, until now experts and the first reports 
suggest recovery in the first two weeks after onset of anosmia, 
but data are still limited. The European Rhinologic Society (ERS) 
and the ENT UK association advise against giving systemic 
corticosteroids to patients with sudden olfactory dysfunction 
since recovery can occur in the first weeks after onset (39, 40). 
Administering topical nasal corticosteroids in patients with an-
osmia remains controversial. The ERS and French Agency ad-
vocate against the use of nasal corticosteroids in patients with 
olfactory and gustatory dysfunction without nasal obstruction 
(40, 41). Although there is no evidence-based indication for 
intranasal corticosteroid, based on expert opinion, the use of 
intranasal corticosteroids can be considered, with a preference 
for spray formulation over gel or drops due to potential viral 
spill to the lower respiratory tract with the latter formulations. 
Also based on expert opinion, if topical corticosteroids are con-
sidered they should be administered with a long applicator so 
the olfactory cleft can be reached (42, 43). There can be a role 
for olfactory training, as it enables improvement of post-in-
fectious olfactory dysfunction in general and it appears to be 
particularly useful in patients who start it within 12 months 
after onset (44). A course of topical vitamin A might be con-
sidered useful (45). In addition, some experts suggested Zinc 
as a useful supplement as this is reported to be beneficial to 
an adequate immune response, can possibly reduce the risk of 
infection and is investigated for its contribution  to olfaction 
as well (46, 47). Some evidence also suggests the potential 
usefulness of lipoic acid and omega 3 in the management of 
olfactory disorders (45, 48).
According to the ENT associations and recent emerging evi-
dence patients presenting with sudden anosmia without nasal 
obstruction should be considered as COVID-19 suspect (28, 
32, 33, 40). Therefore, targeted COVID-19 testing in these 
subjects could be helpful in diagnosing new Sars-CoV-2 in-
fections. Hereby, asymptomatic carriers could be identified as 
soon as possible, and viral transmission could be limited. This 
could also serve as a new criterion for early self-isolation for 
1-2 weeks (28, 41, 49).
Recent studies based on a review of treatment of ARDS sug-
gest no benefit from systemic corticosteroids can be expected 
in COVID-19 cases (50). Because of the immunosuppressive 
properties mentioned by some, this could lead to prolonged 
viral replication and worsening of the condition (50, 51). The 
Centers for Disease Control and Prevention (CDC) and the 
WHO recommend not giving systemic corticosteroids to pa-
tients with COVID-19 pneumonia except for specific case-
based indications (e.g., chronic obstructive lung disease exac-
erbation or septic shock) (19, 52, 53).
According to the ARIA-EEACI (Allergic Rhinitis and its Impact 
on Asthma & European Academy of Allergy and Clinical Immu-
nology) statement, it is advised to continue intranasal cortico-
steroids in patients with allergic rhinitis. Even if they become 
infected by COVID-19, there is no evidence that this could lead 
to deterioration or a worse outcome. It is also contraindicated 
to cease intranasal corticosteroids in patients with a common 
allergy, especially during the spring season, since this could 
lead to more sneezing and thus easier transmission of the virus 
in otherwise asymptomatic carriers (54). Several experts (per-
sonal communication) have the impression that patients with 
type 2 helper T (Th2) cells inflammation such as allergic rhinitis 
(AR) and chronic rhinosinusitis with nasal polyps (CRSwNP) are 
less prone to infection by COVID-19, with only speculation as 
to why this may be the case. Furthermore, nasal corticosteroids 
have been associated with epithelial barrier restoring effects in 
AR and in CRSwNP, hence rendering the mucosa of individuals 
less accessible to external harmful triggers such as viruses (55). 
In addition, a recent study of Zhang et al. reports that patients 
with allergic diseases or asthma are not at an increased risk for 
SARS-CoV-2 infection (56). Therefore, the Global Initiative 
for Asthma (GINA) advises to continue inhaled corticosteroid 
controller medication. They also recommend continuing pre-
scribed oral corticosteroids in severe asthma and during severe 
asthma attacks since this could otherwise lead to dangerous 
situations (57).
Conclusion
The current COVID-19 or Sars-CoV-2 pandemic increased 
awareness of hyposmia or anosmia, as this can be an accom-
panying symptom. In mild cases, anosmia without rhinorrhea 
can be the only presenting symptom of this infection. Timely 
identification can lead to early detection of otherwise asymp-
tomatic carriers. History taking and essential clinical assess-
ment with appropriate protective measures can be performed 
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in patients in whom COVID-19 is suspected. Especially in se-
vere COVID-19 cases, key item in the acute setting is without 
doubt treatment of potentially life-threatening lung disease. 
As for treatment of hyposmia or anosmia, nasal corticoste-
roids can be considered. ENT focus on hyposmia and anosmia 
should be continued, to gain additional knowledge of the dis-
ease mechanisms of COVID-19 and improve follow-up, not 
only on the pneumological aspects but also to evaluate the 
impact on quality of life of potentially long-term side effects 
caused by anosmia.
Recommendations
• Based on currently available literature, the authors do not 
advise treatment with systemic corticosteroids.
• Although there is no evidence-based indication for intra-
nasal corticosteroid, based on expert opinion, the use of 
intranasal corticosteroids can be considered, with a pref-
erence for spray formulation (preferably with a long appli-
cator) over gel or drops due to potential viral spill to the 
lower respiratory tract with the latter formulations.
• Patients who were already using topical or inhalation cor-
ticosteroids for proven pre-existing disease (such as asth-
ma and/or allergy) should be advised to continue their 
maintenance therapy.
• Based on expert opinion, intranasal vitamin A application 
can also be considered.
• Patients with anosmia without nasal obstruction should 
be considered COVID-19 suspect and this should initiate 
testing or self-isolation.
• Follow-up of olfactory testing is indicated, and olfactory 
training can be started in cases where olfactory dysfunc-
tion persists.
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